Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Original Article

T.K. Choueiri, T. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Zurawski, E.Y. Ruiz, M. Maruzzo, A.S. Zaizar, L.E. Fein, F.A. Schutz, D.Y. Heng, F. Wang, F. Mataveli, Y.-L. Chang, M.v.K. Losio, C. Suarez, and R.J. Motzer

N Engl J Med 2023;388:1767-1778

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
05/10/2023
Course expires: 
05/11/2025

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Sunday, May 11, 2025 - 11:59pm.